GENB
Generate Biomedicines·NASDAQ
--
--(--)
--
--(--)
GENB fundamentals
During FY 2025, Generate Biomedicines (GENB) reported revenue of 31.89M, a YoY change of 55.89%. Net income was -222.97M, a YoY change of -22.92%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2024 | FY,2025 | TTM |
|---|
Start Date | Jan 1, 2024 | Jan 1, 2025 | -- |
End Date | Dec 31, 2024 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | -- |
Revenue | 20.46M -- | 31.89M +55.89% | 31.89M -- |
Pretax Income From Continuing Operations | -181.17M -- | -222.80M -22.98% | -222.80M -- |
Income Tax Expense | 212.00K -- | 163.00K -23.11% | 163.00K -- |
Net Income | -181.38M -- | -222.97M -22.92% | -222.97M -- |
Other Comprehensive Income | 69.00K -- | -12.00K -117.39% | -12.00K -- |
Total Comprehensive Income | -181.31M -- | -222.98M -22.98% | -222.98M -- |
Basic EPS | -6.66 -- | -7.57 -13.66% | -7.57 -- |
Diluted EPS | -6.66 -- | -7.57 -13.66% | -7.57 -- |
You can ask Aime
What factors drove the changes in Generate Biomedicines's revenue and profit?What does Generate Biomedicines do and what are its main business segments?What is Generate Biomedicines's latest dividend and current dividend yield?What is Generate Biomedicines's gross profit margin?Did Generate Biomedicines beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Generate Biomedicines year over year?What guidance did Generate Biomedicines's management provide for the next earnings period?What were the key takeaways from Generate Biomedicines’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
